JP2005531574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531574A5 JP2005531574A5 JP2004506808A JP2004506808A JP2005531574A5 JP 2005531574 A5 JP2005531574 A5 JP 2005531574A5 JP 2004506808 A JP2004506808 A JP 2004506808A JP 2004506808 A JP2004506808 A JP 2004506808A JP 2005531574 A5 JP2005531574 A5 JP 2005531574A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- dihydro
- pyrimidin
- trifluoromethylphenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 Phenyl Chemical group 0.000 claims 56
- 125000000217 alkyl group Chemical group 0.000 claims 56
- 125000004429 atom Chemical group 0.000 claims 45
- 229910052760 oxygen Inorganic materials 0.000 claims 42
- 125000005843 halogen group Chemical group 0.000 claims 38
- 229910052717 sulfur Inorganic materials 0.000 claims 33
- 229920006395 saturated elastomer Polymers 0.000 claims 30
- 125000001424 substituent group Chemical group 0.000 claims 30
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims 28
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 11
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 claims 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims 10
- 125000004434 sulfur atom Chemical group 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 150000001412 amines Chemical class 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 208000004296 neuralgia Diseases 0.000 claims 7
- 208000021722 neuropathic pain Diseases 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 6
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 5
- 125000005605 benzo group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- JWPMHRXIIOEZRU-UHFFFAOYSA-N 2,5-dihydro-1,2,4-thiadiazole Chemical compound C1NC=NS1 JWPMHRXIIOEZRU-UHFFFAOYSA-N 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- MKVBVTOSWPBSNC-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,2,4-triazine Chemical compound C1NNC=CN1 MKVBVTOSWPBSNC-UHFFFAOYSA-N 0.000 claims 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 2
- JRLFRFTXXMZSND-UHFFFAOYSA-N 1,2,4-triazoline Chemical compound C1NNC=N1 JRLFRFTXXMZSND-UHFFFAOYSA-N 0.000 claims 2
- USSYLANTAAUELR-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazine Chemical compound N1NC=NC=C1 USSYLANTAAUELR-UHFFFAOYSA-N 0.000 claims 2
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 claims 2
- RMQOXNXLVICLNK-UHFFFAOYSA-N 1,4-dihydro-1,3,5-triazine Chemical compound C1NC=NC=N1 RMQOXNXLVICLNK-UHFFFAOYSA-N 0.000 claims 2
- PNJBXRVMRQIFKK-UHFFFAOYSA-N 1,4-dihydrotriazine Chemical compound C1C=CNN=N1 PNJBXRVMRQIFKK-UHFFFAOYSA-N 0.000 claims 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 claims 2
- CQHHFSBXAPCQFG-UHFFFAOYSA-N 2,3-dihydro-1,2,4-oxadiazole Chemical compound C1NOC=N1 CQHHFSBXAPCQFG-UHFFFAOYSA-N 0.000 claims 2
- ALBVNKOEWADZPF-UHFFFAOYSA-N 2,3-dihydro-1,2,4-thiadiazole Chemical compound C1NSC=N1 ALBVNKOEWADZPF-UHFFFAOYSA-N 0.000 claims 2
- HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical compound C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 claims 2
- IIATVLXXAYLQIZ-UHFFFAOYSA-N 2,5-dihydro-1,2,4-triazine Chemical compound C1C=NNC=N1 IIATVLXXAYLQIZ-UHFFFAOYSA-N 0.000 claims 2
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 claims 2
- RLDJTWKQIMTLEN-UHFFFAOYSA-N 5,6-dihydro-1,4,2-dioxazine Chemical compound C1CON=CO1 RLDJTWKQIMTLEN-UHFFFAOYSA-N 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000002889 sympathetic effect Effects 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- FUIQANIDAMJELP-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,3,5-triazine Chemical compound C1NCN=CN1 FUIQANIDAMJELP-UHFFFAOYSA-N 0.000 claims 1
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 claims 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 claims 1
- JZTKNVMVUVSGJF-UHFFFAOYSA-N 1,2,3,5-oxatriazole Chemical compound C=1N=NON=1 JZTKNVMVUVSGJF-UHFFFAOYSA-N 0.000 claims 1
- XLEDBLKSWOYHES-UHFFFAOYSA-N 1,2,3,5-thiatriazole Chemical compound C=1N=NSN=1 XLEDBLKSWOYHES-UHFFFAOYSA-N 0.000 claims 1
- IOLQWFQLCNMKAZ-UHFFFAOYSA-N 1,2,3,6-tetrahydropyrazine Chemical compound C1CN=CCN1 IOLQWFQLCNMKAZ-UHFFFAOYSA-N 0.000 claims 1
- WNSPCCWAAVHWIM-UHFFFAOYSA-N 1,2,3,6-tetrahydropyridazine Chemical compound C1NNCC=C1 WNSPCCWAAVHWIM-UHFFFAOYSA-N 0.000 claims 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- GBLQGXFTPLQBTA-UHFFFAOYSA-N 1,2,3-triazoline Chemical compound C1CN=NN1 GBLQGXFTPLQBTA-UHFFFAOYSA-N 0.000 claims 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- BLWJJPNXUDWVCG-UHFFFAOYSA-N 1,2,4-oxadiazolidine Chemical compound C1NCON1 BLWJJPNXUDWVCG-UHFFFAOYSA-N 0.000 claims 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 claims 1
- YFCCVJQVYQHMOG-UHFFFAOYSA-N 1,2,4-thiadiazolidine Chemical compound C1NCSN1 YFCCVJQVYQHMOG-UHFFFAOYSA-N 0.000 claims 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 claims 1
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims 1
- WNBQDDAKLKODPH-UHFFFAOYSA-N 1,2,4-triazolidine Chemical compound C1NCNN1 WNBQDDAKLKODPH-UHFFFAOYSA-N 0.000 claims 1
- OYEHFRMFJLFNSD-UHFFFAOYSA-N 1,2,5,6-tetrahydro-1,2,4-triazine Chemical compound C1CN=CNN1 OYEHFRMFJLFNSD-UHFFFAOYSA-N 0.000 claims 1
- OHFXUPDPPRJZES-UHFFFAOYSA-N 1,2,5,6-tetrahydropyrimidine Chemical compound C1CC=NCN1 OHFXUPDPPRJZES-UHFFFAOYSA-N 0.000 claims 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 claims 1
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 claims 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 claims 1
- NTSJGNVMDZAPJE-UHFFFAOYSA-N 1,2-dihydrotriazine Chemical compound N1NN=CC=C1 NTSJGNVMDZAPJE-UHFFFAOYSA-N 0.000 claims 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 1
- SKLDBJVFTOQKHE-UHFFFAOYSA-N 1,3,4-oxadiazolidine Chemical compound C1NNCO1 SKLDBJVFTOQKHE-UHFFFAOYSA-N 0.000 claims 1
- NWEFQXYVAUNGNI-UHFFFAOYSA-N 1,3,4-oxathiazolidine Chemical compound C1NSCO1 NWEFQXYVAUNGNI-UHFFFAOYSA-N 0.000 claims 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims 1
- BRQBVEHLEITSPT-UHFFFAOYSA-N 1,3,4-thiadiazolidine Chemical compound C1NNCS1 BRQBVEHLEITSPT-UHFFFAOYSA-N 0.000 claims 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- UKOMUVPFRFPHDS-UHFFFAOYSA-N 1,4,2-dioxazine Chemical compound O1C=CON=C1 UKOMUVPFRFPHDS-UHFFFAOYSA-N 0.000 claims 1
- DDGWEFMIIOIMEF-UHFFFAOYSA-N 1,4,2-dithiazine Chemical compound S1C=CSN=C1 DDGWEFMIIOIMEF-UHFFFAOYSA-N 0.000 claims 1
- FMYSHKHSQFXYRS-UHFFFAOYSA-N 1,4,2-oxathiazine Chemical compound O1C=CSC=N1 FMYSHKHSQFXYRS-UHFFFAOYSA-N 0.000 claims 1
- GWOPJRXEMFYVQP-UHFFFAOYSA-N 1,4,2-oxathiazolidine Chemical compound C1NOCS1 GWOPJRXEMFYVQP-UHFFFAOYSA-N 0.000 claims 1
- BGMLUCPALPKNOV-UHFFFAOYSA-N 1,4,5,6-tetrahydropyridazine Chemical compound C1CNN=CC1 BGMLUCPALPKNOV-UHFFFAOYSA-N 0.000 claims 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims 1
- XYNBEQAWBCGIMD-UHFFFAOYSA-N 1,4-dihydropyrazine Chemical compound N1C=CNC=C1 XYNBEQAWBCGIMD-UHFFFAOYSA-N 0.000 claims 1
- HZVGMPJZVYBYEK-UHFFFAOYSA-N 1,4-dihydropyridazine Chemical compound C1C=CNN=C1 HZVGMPJZVYBYEK-UHFFFAOYSA-N 0.000 claims 1
- OKGNMRKOGWTADH-UHFFFAOYSA-N 1,4-dihydropyrimidine Chemical compound C1C=CNC=N1 OKGNMRKOGWTADH-UHFFFAOYSA-N 0.000 claims 1
- AKAIWNDBVZJOAJ-UHFFFAOYSA-N 1,4-dithiine Chemical compound S1C=CSC=C1 AKAIWNDBVZJOAJ-UHFFFAOYSA-N 0.000 claims 1
- CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 claims 1
- QFXRFFKVJYBGLQ-UHFFFAOYSA-N 1,6-dihydro-1,2,4-triazine Chemical compound C1NN=CN=C1 QFXRFFKVJYBGLQ-UHFFFAOYSA-N 0.000 claims 1
- ZEFGUWRQFNTGGX-UHFFFAOYSA-N 1,6-dihydropyridazine Chemical compound C1NN=CC=C1 ZEFGUWRQFNTGGX-UHFFFAOYSA-N 0.000 claims 1
- CCLSTLNMIMQGIQ-UHFFFAOYSA-N 1-[3,3-dimethyl-6-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-2h-indol-1-yl]ethanone Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 CCLSTLNMIMQGIQ-UHFFFAOYSA-N 0.000 claims 1
- DWKUKQRKVCMOLP-UHFFFAOYSA-N 1-piperideine Chemical compound C1CCN=CC1 DWKUKQRKVCMOLP-UHFFFAOYSA-N 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 1
- HGYGEJZLUZEDIH-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2,4-triazine Chemical compound C1NCC=NN1 HGYGEJZLUZEDIH-UHFFFAOYSA-N 0.000 claims 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 claims 1
- GRYYTSJXIFGRAL-UHFFFAOYSA-N 2,3-dihydro-1,2,4-triazine Chemical compound C1NN=CC=N1 GRYYTSJXIFGRAL-UHFFFAOYSA-N 0.000 claims 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 claims 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 claims 1
- RZQQXRVPPOOCQR-UHFFFAOYSA-N 2,3-dihydro-1,3,4-oxadiazole Chemical compound C1NN=CO1 RZQQXRVPPOOCQR-UHFFFAOYSA-N 0.000 claims 1
- VKRGLHLCUMMXHA-UHFFFAOYSA-N 2,3-dihydro-1,3,4-thiadiazole Chemical compound C1NN=CS1 VKRGLHLCUMMXHA-UHFFFAOYSA-N 0.000 claims 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 claims 1
- AXYMXGSRCWCVIK-UHFFFAOYSA-N 2,3-dihydro-1,4,2-dioxazine Chemical compound C1NOC=CO1 AXYMXGSRCWCVIK-UHFFFAOYSA-N 0.000 claims 1
- RTQGSDHQFAONPG-UHFFFAOYSA-N 2,3-dihydro-1,4,3-oxathiazine Chemical compound C1NSC=CO1 RTQGSDHQFAONPG-UHFFFAOYSA-N 0.000 claims 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 1
- WUCWFMVYIKMAPG-UHFFFAOYSA-N 2,3-dihydropyrazine Chemical compound C1CN=CC=N1 WUCWFMVYIKMAPG-UHFFFAOYSA-N 0.000 claims 1
- NZHIIDNOLFOHSG-UHFFFAOYSA-N 2,3-dihydropyridine Chemical compound C1CN=CC=C1 NZHIIDNOLFOHSG-UHFFFAOYSA-N 0.000 claims 1
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 claims 1
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 claims 1
- JLPUISACQXFVRC-UHFFFAOYSA-N 2,5-dihydro-1,3-thiazole Chemical compound C1SCN=C1 JLPUISACQXFVRC-UHFFFAOYSA-N 0.000 claims 1
- FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1h-imidazole Chemical compound C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 claims 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims 1
- BNDCYQXUFIHUHS-UHFFFAOYSA-N 2,5-dihydropyrazine Chemical compound C1C=NCC=N1 BNDCYQXUFIHUHS-UHFFFAOYSA-N 0.000 claims 1
- WRLAXLNSBDVNRL-UHFFFAOYSA-N 2,5-dihydropyrimidine Chemical compound C1C=NCN=C1 WRLAXLNSBDVNRL-UHFFFAOYSA-N 0.000 claims 1
- CJUYNKWJWWMLJW-UHFFFAOYSA-N 2,5-dihydrotriazine Chemical compound C1C=NNN=C1 CJUYNKWJWWMLJW-UHFFFAOYSA-N 0.000 claims 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 1
- QUPPDTFXBUVDDC-UHFFFAOYSA-N 2-[5-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]pyridin-2-yl]oxyethanol Chemical compound C1=NC(OCCO)=CC=C1NC1=CC(C=2C=CC(=CC=2)C(F)(F)F)=NC=N1 QUPPDTFXBUVDDC-UHFFFAOYSA-N 0.000 claims 1
- GCHILWAOZLEHGX-UHFFFAOYSA-N 2-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]quinolin-8-ol Chemical compound N1=C2C(O)=CC=CC2=CC=C1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 GCHILWAOZLEHGX-UHFFFAOYSA-N 0.000 claims 1
- PFXWIDHJNPULAS-UHFFFAOYSA-N 2-chloro-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinolin-7-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3N=C(Cl)C=CC3=CC=2)=NC=N1 PFXWIDHJNPULAS-UHFFFAOYSA-N 0.000 claims 1
- RRQUZXQTGWXBDF-UHFFFAOYSA-N 2-chloro-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinolin-8-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C3=NC(Cl)=CC=C3C=CC=2)=NC=N1 RRQUZXQTGWXBDF-UHFFFAOYSA-N 0.000 claims 1
- LDXBDQGGQOIYLQ-UHFFFAOYSA-N 2-methoxy-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinolin-7-amine Chemical compound C=1C2=NC(OC)=CC=C2C=CC=1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 LDXBDQGGQOIYLQ-UHFFFAOYSA-N 0.000 claims 1
- DOCHOMNZLGZLBF-UHFFFAOYSA-N 2-morpholin-4-yl-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinolin-7-amine;hydrochloride Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3N=C(C=CC3=CC=2)N2CCOCC2)=NC=N1 DOCHOMNZLGZLBF-UHFFFAOYSA-N 0.000 claims 1
- TZSMJGAJRFKOPE-UHFFFAOYSA-N 2-n-methyl-7-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinoline-2,7-diamine;dihydrochloride Chemical compound Cl.Cl.C=1C2=NC(NC)=CC=C2C=CC=1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 TZSMJGAJRFKOPE-UHFFFAOYSA-N 0.000 claims 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- HCNVXDPRTRLNFX-UHFFFAOYSA-N 2h-1,3,4-oxadiazine Chemical compound C1OC=CN=N1 HCNVXDPRTRLNFX-UHFFFAOYSA-N 0.000 claims 1
- KLVQAIJZDCCJRZ-UHFFFAOYSA-N 2h-1,3,4-thiadiazine Chemical compound C1SC=CN=N1 KLVQAIJZDCCJRZ-UHFFFAOYSA-N 0.000 claims 1
- PZOJXKYWPGPWQC-UHFFFAOYSA-N 2h-1,3,5-oxadiazine Chemical compound C1OC=NC=N1 PZOJXKYWPGPWQC-UHFFFAOYSA-N 0.000 claims 1
- VNXIZDXJEGBXRQ-UHFFFAOYSA-N 2h-1,3,5-thiadiazine Chemical compound C1SC=NC=N1 VNXIZDXJEGBXRQ-UHFFFAOYSA-N 0.000 claims 1
- NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 claims 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims 1
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 claims 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims 1
- QMDFJHAAWUGVKQ-UHFFFAOYSA-N 2h-thiopyran Chemical compound C1SC=CC=C1 QMDFJHAAWUGVKQ-UHFFFAOYSA-N 0.000 claims 1
- APLXYWOZCKOSMG-UHFFFAOYSA-N 3,4-dihydro-2h-1,2,5-thiadiazine Chemical compound C1CN=CSN1 APLXYWOZCKOSMG-UHFFFAOYSA-N 0.000 claims 1
- LIYUKZAZFWIJPB-UHFFFAOYSA-N 3,4-dihydro-2h-1,3,4-thiadiazine Chemical compound C1NNC=CS1 LIYUKZAZFWIJPB-UHFFFAOYSA-N 0.000 claims 1
- NLXFKDHULKLENC-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-oxazine Chemical compound C1NCC=CO1 NLXFKDHULKLENC-UHFFFAOYSA-N 0.000 claims 1
- VGYDMOUMIQOMMU-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-thiazine Chemical compound C1NCC=CS1 VGYDMOUMIQOMMU-UHFFFAOYSA-N 0.000 claims 1
- YEEGQDGJIXWFIQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-oxazine Chemical compound C1COC=CN1 YEEGQDGJIXWFIQ-UHFFFAOYSA-N 0.000 claims 1
- NARLFVSETWHKRP-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-thiazine Chemical compound C1CSC=CN1 NARLFVSETWHKRP-UHFFFAOYSA-N 0.000 claims 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 claims 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 claims 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 claims 1
- RDOAUPPSCNSYPM-UHFFFAOYSA-N 3,4-dihydropyridine Chemical compound C1CC=NC=C1 RDOAUPPSCNSYPM-UHFFFAOYSA-N 0.000 claims 1
- LPHWCAUEPAUFHZ-UHFFFAOYSA-N 3,6-Dihydropyridine Chemical compound C1C=CCN=C1 LPHWCAUEPAUFHZ-UHFFFAOYSA-N 0.000 claims 1
- MUYVJODFVRCAOF-UHFFFAOYSA-N 3,6-dihydro-1,2,4-triazine Chemical compound C1C=NCN=N1 MUYVJODFVRCAOF-UHFFFAOYSA-N 0.000 claims 1
- YFGWHNJRWZLMPC-UHFFFAOYSA-N 3,6-dihydro-2h-1,2,5-thiadiazine Chemical compound C1NSCN=C1 YFGWHNJRWZLMPC-UHFFFAOYSA-N 0.000 claims 1
- AMKVFOFJZLHHDC-UHFFFAOYSA-N 3,6-dihydro-2h-1,3,4-thiadiazine Chemical compound C1NN=CCS1 AMKVFOFJZLHHDC-UHFFFAOYSA-N 0.000 claims 1
- GPAZGRQYFCWGOO-UHFFFAOYSA-N 3,6-dihydro-2h-1,3,5-thiadiazine Chemical compound C1NC=NCS1 GPAZGRQYFCWGOO-UHFFFAOYSA-N 0.000 claims 1
- RUPLWPYHVWSFEF-UHFFFAOYSA-N 3,6-dihydro-2h-1,3-oxazine Chemical compound C1NC=CCO1 RUPLWPYHVWSFEF-UHFFFAOYSA-N 0.000 claims 1
- UAGQYROKNUIGPX-UHFFFAOYSA-N 3,6-dihydro-2h-1,3-thiazine Chemical compound C1NC=CCS1 UAGQYROKNUIGPX-UHFFFAOYSA-N 0.000 claims 1
- RHOMRSNINFNDIY-UHFFFAOYSA-N 3,6-dihydro-2h-1,4-oxazine Chemical compound C1CN=CCO1 RHOMRSNINFNDIY-UHFFFAOYSA-N 0.000 claims 1
- QTAAKTRBARVAQY-UHFFFAOYSA-N 3,6-dihydro-2h-1,4-thiazine Chemical compound C1CN=CCS1 QTAAKTRBARVAQY-UHFFFAOYSA-N 0.000 claims 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 claims 1
- SGDYNMJTXCTTAF-UHFFFAOYSA-N 3,6-dihydro-2h-thiazine Chemical compound C1NSCC=C1 SGDYNMJTXCTTAF-UHFFFAOYSA-N 0.000 claims 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims 1
- BKYIMUSAVMSMGK-UHFFFAOYSA-N 4,5-dihydropyridazine Chemical compound C1CC=NN=C1 BKYIMUSAVMSMGK-UHFFFAOYSA-N 0.000 claims 1
- BBZZGDLNBVRFFI-UHFFFAOYSA-N 4,5-dihydropyrimidine Chemical compound C1CN=CN=C1 BBZZGDLNBVRFFI-UHFFFAOYSA-N 0.000 claims 1
- ZTPBNDYYCCGCGD-UHFFFAOYSA-N 4,5-dihydrotriazine Chemical compound C1CN=NN=C1 ZTPBNDYYCCGCGD-UHFFFAOYSA-N 0.000 claims 1
- GYIAMGNLNAANAL-UHFFFAOYSA-N 4-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-2H-1,3-benzothiazole-2,4-diamine Chemical compound FC(C1=CC=C(C=C1)C1=CC(=NC=N1)C1(C=CC=C2C1=NC(S2)N)N)(F)F GYIAMGNLNAANAL-UHFFFAOYSA-N 0.000 claims 1
- UBVWUWPEFCMAAR-UHFFFAOYSA-N 4-methyl-7-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1h-quinolin-2-one Chemical compound C=1C=C2C(C)=CC(O)=NC2=CC=1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 UBVWUWPEFCMAAR-UHFFFAOYSA-N 0.000 claims 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 claims 1
- NGUCKHVSIWZIPQ-UHFFFAOYSA-N 4h-1,2,5-oxadiazine Chemical compound C1C=NOC=N1 NGUCKHVSIWZIPQ-UHFFFAOYSA-N 0.000 claims 1
- QBMIYRSEKPGOJY-UHFFFAOYSA-N 4h-1,3,4-oxadiazine Chemical compound N1C=COC=N1 QBMIYRSEKPGOJY-UHFFFAOYSA-N 0.000 claims 1
- AVHCHJKMIGPLIZ-UHFFFAOYSA-N 4h-1,3,4-thiadiazine Chemical compound N1C=CSC=N1 AVHCHJKMIGPLIZ-UHFFFAOYSA-N 0.000 claims 1
- LPWMFGGUZLCGBF-UHFFFAOYSA-N 4h-1,3,5-oxadiazine Chemical compound C1N=COC=N1 LPWMFGGUZLCGBF-UHFFFAOYSA-N 0.000 claims 1
- QLOAZIIJBGXVDN-UHFFFAOYSA-N 4h-1,3,5-thiadiazine Chemical compound C1N=CSC=N1 QLOAZIIJBGXVDN-UHFFFAOYSA-N 0.000 claims 1
- IQOZTIKBIHWYQQ-UHFFFAOYSA-N 4h-1,3-oxazine Chemical compound C1C=COC=N1 IQOZTIKBIHWYQQ-UHFFFAOYSA-N 0.000 claims 1
- UOSQFVCDJBZRKS-UHFFFAOYSA-N 4h-1,4-oxazine Chemical compound N1C=COC=C1 UOSQFVCDJBZRKS-UHFFFAOYSA-N 0.000 claims 1
- ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 4h-1,4-thiazine Chemical compound N1C=CSC=C1 ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 0.000 claims 1
- BMRPOOWUTVUBRI-UHFFFAOYSA-N 4h-oxazine Chemical compound C1C=CON=C1 BMRPOOWUTVUBRI-UHFFFAOYSA-N 0.000 claims 1
- XZMWWZZCMGYPHD-UHFFFAOYSA-N 4h-thiazine Chemical compound C1C=CSN=C1 XZMWWZZCMGYPHD-UHFFFAOYSA-N 0.000 claims 1
- STBGWNRZMPCVTG-UHFFFAOYSA-N 4h-thiopyran Chemical compound C1C=CSC=C1 STBGWNRZMPCVTG-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- VNOMHCXUKPUGJE-UHFFFAOYSA-N 5,6-dihydro-1,2,4-triazine Chemical compound C1CN=NC=N1 VNOMHCXUKPUGJE-UHFFFAOYSA-N 0.000 claims 1
- SGVDPBAZOBRHRE-UHFFFAOYSA-N 5,6-dihydro-1,4,2-dithiazine Chemical compound C1CSN=CS1 SGVDPBAZOBRHRE-UHFFFAOYSA-N 0.000 claims 1
- VXBRQDSRTRLHPJ-UHFFFAOYSA-N 5,6-dihydro-1,4,2-oxathiazine Chemical compound C1CSC=NO1 VXBRQDSRTRLHPJ-UHFFFAOYSA-N 0.000 claims 1
- QUJTVGHTSQMUMV-UHFFFAOYSA-N 5,6-dihydro-1,4,3-oxathiazine Chemical compound C1CSN=CO1 QUJTVGHTSQMUMV-UHFFFAOYSA-N 0.000 claims 1
- OWKSGFQMLODDJJ-UHFFFAOYSA-N 5,6-dihydro-2h-1,2,5-thiadiazine Chemical compound C1NC=CNS1 OWKSGFQMLODDJJ-UHFFFAOYSA-N 0.000 claims 1
- LUSYNJGQFRRKIA-UHFFFAOYSA-N 5,6-dihydro-2h-1,3-oxazine Chemical compound C1CC=NCO1 LUSYNJGQFRRKIA-UHFFFAOYSA-N 0.000 claims 1
- NXNZBSJCMSODTO-UHFFFAOYSA-N 5,6-dihydro-2h-1,3-thiazine Chemical compound C1CC=NCS1 NXNZBSJCMSODTO-UHFFFAOYSA-N 0.000 claims 1
- UFTHEDBYLPFRDP-UHFFFAOYSA-N 5,6-dihydro-2h-oxazine Chemical compound C1CC=CNO1 UFTHEDBYLPFRDP-UHFFFAOYSA-N 0.000 claims 1
- MXDHUJDGSBTOTI-UHFFFAOYSA-N 5,6-dihydro-2h-thiadiazine Chemical compound C1CC=NNS1 MXDHUJDGSBTOTI-UHFFFAOYSA-N 0.000 claims 1
- MSTFRUQNYRRUKZ-UHFFFAOYSA-N 5,6-dihydro-2h-thiazine Chemical compound C1CC=CNS1 MSTFRUQNYRRUKZ-UHFFFAOYSA-N 0.000 claims 1
- OXHGKAXWARAOPZ-UHFFFAOYSA-N 5,6-dihydro-4h-1,2,5-thiadiazine Chemical compound C1NCC=NS1 OXHGKAXWARAOPZ-UHFFFAOYSA-N 0.000 claims 1
- ZQNUENDKDTXKSU-UHFFFAOYSA-N 5,6-dihydro-4h-1,3,4-thiadiazine Chemical compound C1CSC=NN1 ZQNUENDKDTXKSU-UHFFFAOYSA-N 0.000 claims 1
- YWOIQIYQBRDOQA-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-oxazine Chemical compound C1COC=NC1 YWOIQIYQBRDOQA-UHFFFAOYSA-N 0.000 claims 1
- YPXAASDZAZBHMG-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-thiazine Chemical compound C1CSC=NC1 YPXAASDZAZBHMG-UHFFFAOYSA-N 0.000 claims 1
- BYVSMDBDTBXASR-UHFFFAOYSA-N 5,6-dihydro-4h-oxazine Chemical compound C1CON=CC1 BYVSMDBDTBXASR-UHFFFAOYSA-N 0.000 claims 1
- WSXNRJXPTNQJBH-UHFFFAOYSA-N 5,6-dihydro-4h-thiazine Chemical compound C1CSN=CC1 WSXNRJXPTNQJBH-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- UWRVKARAIZSLHI-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-n-naphthalen-1-ylpyrimidin-4-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(NC=2C3=CC=CC=C3C=CC=2)=NC=N1 UWRVKARAIZSLHI-UHFFFAOYSA-N 0.000 claims 1
- RQQRLEWZUAUFEW-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-n-phenylpyrimidin-4-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(NC=2C=CC=CC=2)=NC=N1 RQQRLEWZUAUFEW-UHFFFAOYSA-N 0.000 claims 1
- GYPNVCZUTNOERU-UHFFFAOYSA-N 6-[[6-(4-tert-butylphenyl)pyrimidin-4-yl]amino]-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(NC=2C=C3CCCC(=O)C3=CC=2)=NC=N1 GYPNVCZUTNOERU-UHFFFAOYSA-N 0.000 claims 1
- MIOUOWAIZBEKFY-UHFFFAOYSA-N 6h-1,2,5-oxadiazine Chemical compound C1ON=CC=N1 MIOUOWAIZBEKFY-UHFFFAOYSA-N 0.000 claims 1
- BMZKZBWPMWEQAY-UHFFFAOYSA-N 6h-1,2,5-thiadiazine Chemical compound C1SN=CC=N1 BMZKZBWPMWEQAY-UHFFFAOYSA-N 0.000 claims 1
- BTSRCKGXYLBFOS-UHFFFAOYSA-N 6h-1,3,4-oxadiazine Chemical compound C1OC=NN=C1 BTSRCKGXYLBFOS-UHFFFAOYSA-N 0.000 claims 1
- BJZFKUQYNPYBGE-UHFFFAOYSA-N 6h-1,3,4-thiadiazine Chemical compound C1SC=NN=C1 BJZFKUQYNPYBGE-UHFFFAOYSA-N 0.000 claims 1
- GMLMFZXBPRIXPK-UHFFFAOYSA-N 6h-1,3-oxazine Chemical compound C1OC=NC=C1 GMLMFZXBPRIXPK-UHFFFAOYSA-N 0.000 claims 1
- VNCVSCGVODHWLX-UHFFFAOYSA-N 6h-1,3-thiazine Chemical compound C1SC=NC=C1 VNCVSCGVODHWLX-UHFFFAOYSA-N 0.000 claims 1
- QFPDHKBNCJAOKJ-UHFFFAOYSA-N 6h-oxazine Chemical compound C1ON=CC=C1 QFPDHKBNCJAOKJ-UHFFFAOYSA-N 0.000 claims 1
- DLNUKTLHURJVDF-UHFFFAOYSA-N 6h-thiazine Chemical compound C1SN=CC=C1 DLNUKTLHURJVDF-UHFFFAOYSA-N 0.000 claims 1
- BXYWRQOHMPGTQH-UHFFFAOYSA-N 7-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-6H-quinoline-2,7-diamine Chemical compound FC(C1=CC=C(C=C1)C1=CC(=NC=N1)C1(CC=C2C=CC(=NC2=C1)N)N)(F)F BXYWRQOHMPGTQH-UHFFFAOYSA-N 0.000 claims 1
- UWNAEPYAUOFGML-UHFFFAOYSA-N 7-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1h-quinolin-2-one Chemical compound C=1C2=NC(O)=CC=C2C=CC=1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 UWNAEPYAUOFGML-UHFFFAOYSA-N 0.000 claims 1
- HHYRMTZDDRKOEV-UHFFFAOYSA-N 7-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3NC(=O)CCC3=CC=2)=NC=N1 HHYRMTZDDRKOEV-UHFFFAOYSA-N 0.000 claims 1
- JVHGRMZIVGIQNA-UHFFFAOYSA-N 8-n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]quinoline-2,8-diamine Chemical compound C12=NC(N)=CC=C2C=CC=C1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 JVHGRMZIVGIQNA-UHFFFAOYSA-N 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- CCVRDKFBCDVQBY-UHFFFAOYSA-N C1NC=CN=N1 Chemical compound C1NC=CN=N1 CCVRDKFBCDVQBY-UHFFFAOYSA-N 0.000 claims 1
- QVUUBNJHJQJXDY-UHFFFAOYSA-N Cl.S1C=NC2=C1C=C(C=C2)C2(NC(=NC(=C2)C2=CC=C(C=C2)C(C)(C)C)N)N Chemical compound Cl.S1C=NC2=C1C=C(C=C2)C2(NC(=NC(=C2)C2=CC=C(C=C2)C(C)(C)C)N)N QVUUBNJHJQJXDY-UHFFFAOYSA-N 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 206010061619 Deformity Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- VVMDNIKATDDFHZ-UHFFFAOYSA-N N1C=NCCC1.N1CNCC=C1 Chemical compound N1C=NCCC1.N1CNCC=C1 VVMDNIKATDDFHZ-UHFFFAOYSA-N 0.000 claims 1
- URKIKPNSDQQUNJ-UHFFFAOYSA-N O1CCSCC1.O1CCOCC1 Chemical compound O1CCSCC1.O1CCOCC1 URKIKPNSDQQUNJ-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- MOGLBIRJEBMVJL-UHFFFAOYSA-N S1N=CNC1.O1NC=NC1 Chemical compound S1N=CNC1.O1NC=NC1 MOGLBIRJEBMVJL-UHFFFAOYSA-N 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- IILNJROFHMSYJR-OAHLLOKOSA-N [(2r)-6-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxin-2-yl]methanol Chemical compound C([C@H](OC1=CC=2)CO)OC1=CC=2NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 IILNJROFHMSYJR-OAHLLOKOSA-N 0.000 claims 1
- SINWESYUDUSEKY-UHFFFAOYSA-N [7-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1h-indol-2-yl]methanol Chemical compound C=12NC(CO)=CC2=CC=CC=1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 SINWESYUDUSEKY-UHFFFAOYSA-N 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- IHGHAGMNQGGSRI-UHFFFAOYSA-N n-(3-methylsulfonylphenyl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-amine Chemical compound CS(=O)(=O)C1=CC=CC(NC=2N=CN=C(C=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 IHGHAGMNQGGSRI-UHFFFAOYSA-N 0.000 claims 1
- LUNAKSUVRLRDTA-UHFFFAOYSA-N n-[4-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=CC=C2SC(NC(=O)C)=NC2=C1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 LUNAKSUVRLRDTA-UHFFFAOYSA-N 0.000 claims 1
- UCAUQOHOWKFRJN-UHFFFAOYSA-N n-[4-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]-1h-benzimidazol-2-yl]acetamide Chemical compound C1=CC=C2NC(NC(=O)C)=NC2=C1NC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 UCAUQOHOWKFRJN-UHFFFAOYSA-N 0.000 claims 1
- LDYJMXZHWCVICG-UHFFFAOYSA-N n-[4-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=CC(C=2C=CC(=CC=2)C(F)(F)F)=NC=N1 LDYJMXZHWCVICG-UHFFFAOYSA-N 0.000 claims 1
- RUASTSAKDYDXCE-UHFFFAOYSA-N n-[5-(4-tert-butylphenyl)-6-phenylpyridazin-3-yl]-1h-indol-5-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC(NC=2C=C3C=CNC3=CC=2)=NN=C1C1=CC=CC=C1 RUASTSAKDYDXCE-UHFFFAOYSA-N 0.000 claims 1
- HDEGHWQWPSXKSF-UHFFFAOYSA-N n-[6-[2-(cyclohexylmethylamino)-4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1,3-benzothiazol-6-amine Chemical compound C=1C(C(F)(F)F)=CC=C(C=2N=CN=C(NC=3C=C4SC=NC4=CC=3)C=2)C=1NCC1CCCCC1 HDEGHWQWPSXKSF-UHFFFAOYSA-N 0.000 claims 1
- UZRPYNKOTGQCOR-UHFFFAOYSA-N n-[6-[2-amino-4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1,3-benzothiazol-6-amine Chemical compound NC1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3SC=NC3=CC=2)=NC=N1 UZRPYNKOTGQCOR-UHFFFAOYSA-N 0.000 claims 1
- JBHBWYZHCBRNNE-UHFFFAOYSA-N n-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1h-benzimidazol-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=3N=CNC=3C=CC=2)=NC=N1 JBHBWYZHCBRNNE-UHFFFAOYSA-N 0.000 claims 1
- UMQGPDQIQVFMDQ-UHFFFAOYSA-N n-[6-chloro-5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl]-1,3-benzothiazol-6-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3SC=NC3=CC=2)=NN=C1Cl UMQGPDQIQVFMDQ-UHFFFAOYSA-N 0.000 claims 1
- QHIBPOUPRABWEM-UHFFFAOYSA-N n-[6-naphthalen-2-yl-5-[4-(trifluoromethyl)phenyl]pyridazin-3-yl]-1,3-benzothiazol-6-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(NC=2C=C3SC=NC3=CC=2)=NN=C1C1=CC=C(C=CC=C2)C2=C1 QHIBPOUPRABWEM-UHFFFAOYSA-N 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 claims 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000009092 tissue dysfunction Effects 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38333102P | 2002-05-22 | 2002-05-22 | |
| PCT/US2003/016655 WO2003099284A1 (en) | 2002-05-22 | 2003-05-20 | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531574A JP2005531574A (ja) | 2005-10-20 |
| JP2005531574A5 true JP2005531574A5 (https=) | 2006-07-06 |
Family
ID=29584545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506808A Withdrawn JP2005531574A (ja) | 2002-05-22 | 2003-05-20 | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7053088B2 (https=) |
| EP (1) | EP1542692B1 (https=) |
| JP (1) | JP2005531574A (https=) |
| AT (1) | ATE493987T1 (https=) |
| AU (1) | AU2003247425B2 (https=) |
| CA (1) | CA2486376A1 (https=) |
| DE (1) | DE60335635D1 (https=) |
| ES (1) | ES2355472T3 (https=) |
| MX (1) | MXPA04011472A (https=) |
| PL (1) | PL375552A1 (https=) |
| WO (1) | WO2003099284A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011472A (es) * | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| EP1569925A1 (en) * | 2002-12-13 | 2005-09-07 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| GB0310726D0 (en) | 2003-05-09 | 2003-06-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA2531490A1 (en) * | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| EP1670794A2 (en) | 2003-09-30 | 2006-06-21 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005047279A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| WO2005073193A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| MY139645A (en) * | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| AU2005212438A1 (en) | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| RU2361872C2 (ru) * | 2004-05-26 | 2009-07-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Циннамидное соединение |
| US7762951B2 (en) * | 2004-06-25 | 2010-07-27 | Medtronic, Inc. | Vein harvesting system including dilator shaft and removable retractor housing |
| WO2006006740A1 (ja) * | 2004-07-14 | 2006-01-19 | Japan Tobacco Inc. | ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| MX2007000480A (es) * | 2004-07-15 | 2007-03-29 | Japan Tobacco Inc | Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1. |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| WO2006029209A2 (en) * | 2004-09-07 | 2006-03-16 | Smithkline Beecham Corporation | Method for activating trpv4 channel receptors by agonists |
| AU2005284904A1 (en) * | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2006038041A1 (en) * | 2004-10-08 | 2006-04-13 | Merck Sharp & Dohme Limited | Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| EP1807418A2 (en) * | 2004-10-22 | 2007-07-18 | Amgen, Inc | Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament |
| DE602005019602D1 (de) * | 2004-10-26 | 2010-04-08 | Eisai R&D Man Co Ltd | Amorphe form einer zimtsäureamidverbindung |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| WO2006113769A1 (en) * | 2005-04-15 | 2006-10-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US20060241296A1 (en) * | 2005-04-25 | 2006-10-26 | Doherty Elizabeth M | Vanilloid receptor ligands and their use in treatments |
| DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005023784A1 (de) * | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005044813A1 (de) * | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| NZ565080A (en) | 2005-07-22 | 2011-03-31 | Mochida Pharm Co Ltd | Novel heterocyclidene acetamide derivative |
| AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| CA2619768A1 (en) * | 2005-08-19 | 2007-02-22 | The Regents Of The University Of California | Use of seh inhibitors as analgesics |
| CN101309916A (zh) * | 2005-11-18 | 2008-11-19 | 卫材R&D管理有限公司 | 制备肉桂酰胺衍生物的方法 |
| US20090048448A1 (en) * | 2005-11-18 | 2009-02-19 | Ikuo Kushida | Salts of cynnamide compound or solvates thereof |
| KR20080069221A (ko) * | 2005-11-24 | 2008-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모르폴린 타입의 신나미드 화합물 |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| US7709501B2 (en) * | 2005-12-23 | 2010-05-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1967519B1 (en) | 2005-12-28 | 2012-09-05 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| US7737141B2 (en) * | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
| WO2008061112A2 (en) * | 2006-11-14 | 2008-05-22 | Myriad Genetics, Inc. | Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof |
| CL2008000582A1 (es) * | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
| US20080306272A1 (en) * | 2007-05-16 | 2008-12-11 | Eisai R&D Management Co., Ltd. | One-pot methods for preparing cinnamide derivatives |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| BRPI0815773A2 (pt) | 2007-08-31 | 2019-09-24 | Eisai R&D Man Co Ltd | composto, e, medicamento. |
| WO2009038812A1 (en) * | 2007-09-20 | 2009-03-26 | Amgen Inc. | Condensed piperidine derivatives useful as vanilloid receptor ligands |
| WO2009096349A1 (ja) * | 2008-01-28 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 結晶性のシンナミド化合物またはその塩 |
| WO2009096701A2 (en) | 2008-01-28 | 2009-08-06 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| JP5372138B2 (ja) | 2008-04-18 | 2013-12-18 | テウン ファーマシューティカル カンパニー，リミテッド | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| JP5438103B2 (ja) | 2008-07-02 | 2014-03-12 | アモーレパシフィック コーポレイション | バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物 |
| EP2306975A4 (en) | 2008-07-21 | 2012-10-31 | Otonomy Inc | COMPOSITIONS WITH A TAXED RELEASE FOR MODULATING THE EARM STRUCTURE AND THE BORN IMMUNE SYSTEM, AND METHODS OF TREATING EAR OR DISEASE |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| EP2266972A1 (en) * | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| WO2011117198A2 (en) * | 2010-03-23 | 2011-09-29 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN105530938B (zh) | 2013-07-05 | 2019-10-22 | Abivax公司 | 用于治疗由逆转录病毒引起的疾病的化合物 |
| US9717797B2 (en) | 2013-12-05 | 2017-08-01 | International Business Machines Corporation | Polycarbonates bearing aromatic N-heterocycles for drug delivery |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
| AU2017290256A1 (en) | 2016-06-29 | 2019-01-17 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) * | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| US3707560A (en) * | 1970-10-05 | 1972-12-26 | Pfizer | Certain 4-amino-6-aryl-pyrimidines |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
| US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
| US5461053A (en) | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
| IL118469A (en) * | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| EA001450B1 (ru) | 1996-05-01 | 2001-04-23 | Эли Лилли Энд Компани | Галогензамещенные ингибиторы протеинкиназы с |
| CA2266639A1 (en) * | 1996-09-23 | 1998-03-26 | Rajeshwar Singh | 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
| US5916887A (en) | 1996-09-23 | 1999-06-29 | National Research Council Of Canada | 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2276081A1 (en) | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
| US6093737A (en) * | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| BR9812041B1 (pt) * | 1997-09-05 | 2009-08-11 | processo para a preparação de derivados n-acilados (hetero) aromáticos da hidroxilamina. | |
| CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
| EP1054882A1 (fr) | 1998-02-13 | 2000-11-29 | Aventis Pharma S.A. | Derives de systemes heterocycliques condenses, leur preparation, les compositions pharmaceutiques qui les contiennent |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| GB9907683D0 (en) * | 1999-04-06 | 1999-05-26 | Synphar Lab Inc | Substituted azetidin-2-ones as cysteine protease inhibitors |
| KR20020063837A (ko) | 1999-07-19 | 2002-08-05 | 시오노기세이야쿠가부시키가이샤 | 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물 |
| BR0012697A (pt) | 1999-07-23 | 2002-04-09 | Shionogi & Co | Inibidores da diferenciação de th2 |
| WO2001007401A1 (en) | 1999-07-23 | 2001-02-01 | Shionogi & Co., Ltd. | Tricyclic compounds and drug compositions containing the same |
| BR0013551A (pt) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| US6602872B1 (en) * | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| KR20030009416A (ko) | 2000-04-04 | 2003-01-29 | 시오노기세이야쿠가부시키가이샤 | 고지용성 약물을 함유하는 유성 조성물 |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| US20030176454A1 (en) | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
| GB0014022D0 (en) | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| WO2002012198A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| KR20030029878A (ko) | 2000-08-30 | 2003-04-16 | 다우 아그로사이언시즈 엘엘씨 | 살충제로서 유용한 화합물, 살비제로서 유용한 화합물 및,이들의 사용방법 및 제조방법 |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20040067938A1 (en) | 2000-09-29 | 2004-04-08 | Penglie Zhang | Quaternary amines and related inhibitors of factor xa |
| SE0004053D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| WO2002050052A1 (en) | 2000-12-20 | 2002-06-27 | Syngenta Participations Ag | N-acyl aminoacetonitriles having pesticidal properties |
| CA2441733A1 (en) | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2002080853A2 (en) | 2001-04-09 | 2002-10-17 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| EP1389616B1 (en) | 2001-04-27 | 2011-07-27 | Mitsubishi Tanabe Pharma Corporation | 3,4-Dihalobenzylpiperidine derivatives and their medical use |
| WO2002096867A2 (en) * | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| AU2002367752A1 (en) | 2001-10-03 | 2003-11-17 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| JP2005509606A (ja) | 2001-10-03 | 2005-04-14 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ |
| WO2003041649A2 (en) | 2001-11-13 | 2003-05-22 | Merck Frosst Canada & Co. | Cyanoalkylamino derivatives as protease inhibitors |
| EP1470121B1 (en) * | 2002-01-23 | 2012-07-11 | Bayer HealthCare LLC | Pyrimidine derivatives as rho-kinase inhibitors |
| MXPA04011472A (es) * | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| AU2005284904A1 (en) * | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
-
2003
- 2003-05-20 MX MXPA04011472A patent/MXPA04011472A/es active IP Right Grant
- 2003-05-20 CA CA002486376A patent/CA2486376A1/en not_active Abandoned
- 2003-05-20 WO PCT/US2003/016655 patent/WO2003099284A1/en not_active Ceased
- 2003-05-20 PL PL03375552A patent/PL375552A1/xx not_active Application Discontinuation
- 2003-05-20 US US10/445,170 patent/US7053088B2/en not_active Expired - Fee Related
- 2003-05-20 EP EP03755509A patent/EP1542692B1/en not_active Expired - Lifetime
- 2003-05-20 JP JP2004506808A patent/JP2005531574A/ja not_active Withdrawn
- 2003-05-20 AU AU2003247425A patent/AU2003247425B2/en not_active Ceased
- 2003-05-20 AT AT03755509T patent/ATE493987T1/de not_active IP Right Cessation
- 2003-05-20 DE DE60335635T patent/DE60335635D1/de not_active Expired - Lifetime
- 2003-05-20 ES ES03755509T patent/ES2355472T3/es not_active Expired - Lifetime
-
2005
- 2005-08-01 US US11/195,302 patent/US7524874B2/en not_active Expired - Fee Related
- 2005-08-01 US US11/195,303 patent/US7396831B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531574A5 (https=) | ||
| WO2003099284B1 (en) | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain | |
| CA2493667A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| JP2005518371A5 (https=) | ||
| JP7817170B2 (ja) | 小分子ｓｔｉｎｇアンタゴニスト | |
| ES2328671T3 (es) | Compuestos de piperazilpirazinas como antagonistas del receptor de serotonina 5-ht2. | |
| JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
| AU2002364549B2 (en) | Vanilloid receptor ligands and their use in treatments | |
| JP6751203B2 (ja) | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 | |
| DK2937341T3 (en) | 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS | |
| RU2028297C1 (ru) | Производные пиримидин-4-она или их фармацевтически приемлемые соли и серотонинантагонистическая, допаминантагонистическая и антигистаминная композиция на их основе | |
| RU2333198C2 (ru) | Производные бензамида или фармацевтически приемлемые соли указанного производного, фармацевтическая композиция на их основе и применение | |
| CA2823877C (en) | Novel pyrazole and imidazole derivatives useful as orexin antagonists | |
| JP2007533635A (ja) | バニロイド受容体リガンドおよび治療おけるこれらの使用 | |
| JP2009507849A (ja) | 非環状ＩＫｕｒインヒビター | |
| HUP0003073A2 (hu) | Benzolszulfonamid-származékok, eljárás előállításukra és gyógyszerként való alkalmazásuk | |
| KR20060041242A (ko) | 5ｈｔ1-타입 수용체에 대해 친화성을 갖는 퀴놀린 및퀴나졸린 유도체 | |
| HUP0401898A2 (hu) | 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik | |
| KR20110071004A (ko) | 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체 | |
| JPH10500960A (ja) | ５ｈｔ１ｄ−アンタゴニスト活性を有するアミド誘導体 | |
| TW201925186A (zh) | 用於作為shp2抑制劑之新穎雜環衍生物 | |
| AU2005284904A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| JPH05194441A (ja) | 新規な置換３−ピペラジニルアルキル−２，３−ジヒドロ−４ｈ−１，３−ベンゾオキサジン−４−オン、その製造法および治療用途 | |
| JP2011518152A (ja) | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 | |
| KR20050044852A (ko) | 가스트린으로서의 벤조트리아제핀들 및 콜레시스토키닌수용체 리간드들 |